A
Alnylam Pharmaceuticals
Develops novel therapeutics-based RNAi and provides overviews of recent drug development programs
At a glance
- Founded
- 2002
- Headquarters
- Cambridge, United States
- Listing
- IPO 2004
- Sector
- Biotech & Life Sciences
- Power Law
- Decacorn$10B+ valuation tierThoroughbred$100M+ revenue
Latest news
Press, funding announcements and product moves mentioning Alnylam Pharmaceuticals.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later9 investors entered at this stage
- MTMassachusetts Institute of Technology
- ABAbingworth
Polaris Partners
ARCH Venture Partners
Atlas Venture- CPCardinal Partners
- MSMax Planck Society
- MIMax Planck Innovation
- MCMerck & Co.
Source: Dealroom Talent Intelligence.
Alumni founders
Former Alnylam Pharmaceuticals employees who went on to found companies, sorted by Dealroom signal score.
SRScholar RockEst. 2012
Nagesh MahanthappaUnited States
AEAerskaEst. 2025
IPImbria PharmaceuticalsEst. 2018
David-Alexandre "Da" GrosUnited States
ABArpeggio BioEst. 2017
Tim ReadUnited StatesGlobal footprint
team presence
across markets
Patents
467 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Alnylam Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Alnylam Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.